Atonco publishes its November 2025 report outlining the state of clinical research in alphatherapy worldwide. Compiled from ClinicalTrials.gov databases and recent scientific publications, this document maps all clinical trials conducted and ongoing with the three next-generation alpha-emitting radioisotopes: Actinium-225, Lead-212, and Astatine-211. This analysis identifies major players, their strategic choices regarding therapeutic targets and clinical indications, as well as industrial prospects for large-scale deployment of these promising technologies.<\/p>\n
Clinical alphatherapy is experiencing significant growth with 28 Phase 1 or 1\/2 studies registered in 2025, involving both pharmaceutical giants (AstraZeneca, Bayer, BMS, J&J, Eli Lilly, Novartis) and numerous innovative biotechs. The three radioisotopes currently in development \u2013 Actinium-225 (14 studies), Lead-212 (6 studies), and Astatine-211 (8 studies) \u2013 share a decisive advantage: their linear energy transfer is 100 times higher than Lutetium-177, inducing irreparable double-strand DNA breaks in tumor cells. While Actinium-225 dominates clinical trials thanks to its 10-day half-life allowing long-distance transport, Astatine-211 stands out for its safe production in conventional cyclotrons and absence of long-lived toxic daughter nuclides. In this context, Atonco has demonstrated the clinical feasibility of intravesical instillation of anti-CAIX-labeled antibodies, confirming excellent bladder retention and superior radiocytotoxicity of Astatine-211.<\/p>\n